LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+24.76%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$724M
AUM Growth
+$724M
(+3.6%)
Cap. Flow
-$84M
Cap. Flow
% of AUM
-11.6%
Top 10 Holdings %
Top 10 Hldgs %
51.97%
Holding
60
New
17
Increased
7
Reduced
18
Closed
10
Top Buys
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$21.5M |
| 2 |
Arcellx
ACLX
|
$15.8M |
| 3 |
Arcus Biosciences
RCUS
|
$15.2M |
| 4 |
Cytokinetics
CYTK
|
$13M |
| 5 |
Annexon
ANNX
|
$12.3M |
Top Sells
| 1 |
IDEAYA Biosciences
IDYA
|
$43.5M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$37M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$24.1M |
| 4 |
Ascendis Pharma
ASND
|
$16.1M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$15.9M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $56.9M | 7.74% | 625,000 -175,000 | -22% | -$15.9M |
|
|
2
Cytokinetics
CYTK
$4.23B
| $53.8M | 7.32% | 1,650,000 +400,000 | +32% | +$13M |
|
3
Immunovant
IMVT
$2.56B
| $42.7M | 5.81% | 2,250,000 -250,000 | -10% | -$4.74M |
|
|
4
IDEAYA Biosciences
IDYA
$2.15B
| $41.1M | 5.59% | 1,750,000 -1,850,000 | -51% | -$43.5M |
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $34.4M | 4.67% | 300,000 +80,000 | +36% | +$9.16M |
|
6
Olema Pharmaceuticals
OLMA
$375M
| $33.8M | 4.6% | 3,743,875 | – | – |
|
7
Immunocore
IMCR
$1.62B
| $30M | 4.08% | 500,000 | – | – |
|
8
Biogen
BIIB
$19.4B
| $28.5M | 3.87% | 100,000 | – | – |
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $28.3M | 3.85% | 300,000 +100,000 | +50% | +$9.43M |
|
10
Viridian Therapeutics
VRDN
$1.5B
| $26.8M | 3.64% | 1,125,000 +175,000 | +18% | +$4.16M |
|
11
Akero Therapeutics
AKRO
$3.74B
| $24.3M | 3.3% | 520,000 +120,000 | +30% | +$5.6M |
|
|
ALLK
12
DELISTED
Allakos
ALLK
| $22.9M | 3.11% | 5,250,000 -286,666 | -5% | -$1.25M |
|
|
ICVX
13
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $21.5M | 2.93% | +2,165,741 | New | +$21.5M |
|
14
Dyne Therapeutics
DYN
$1.92B
| $20M | 2.72% | 1,780,000 +80,000 | +5% | +$900K |
|
15
Design Therapeutics
DSGN
$315M
| $17.6M | 2.4% | 2,797,501 | – | – |
|
16
Structure Therapeutics
GPCR
$1.11B
| $16.6M | 2.26% | 400,000 +50,000 | +14% | +$2.08M |
|
|
17
Arcellx
ACLX
$3.85B
| $15.8M | 2.15% | +500,000 | New | +$15.8M |
|
|
18
Arcus Biosciences
RCUS
$1.13B
| $15.2M | 2.07% | +750,000 | New | +$15.2M |
|
|
BCYC
19
Bicycle Therapeutics
BCYC
$511M
| $13.3M | 1.81% | 520,000 -230,000 | -31% | -$5.87M |
|
|
20
Annexon
ANNX
$226M
| $12.3M | 1.68% | +3,500,000 | New | +$12.3M |
|
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $10.6M | 1.44% | 275,000 -625,000 | -69% | -$24.1M |
|
22
Galapagos
GLPG
$2.07B
| $10.2M | 1.38% | 250,000 -100,000 | -29% | -$4.07M |
|
23
Cogent Biosciences
COGT
$1.69B
| $9.47M | 1.29% | 800,000 -200,000 | -20% | -$2.37M |
|
24
Mersana Therapeutics
MRSN
$36.5M
| $9.21M | 1.25% | +2,800,000 | New | +$9.21M |
|
|
MOR
25
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $8.96M | 1.22% | 1,200,000 -300,000 | -20% | -$2.24M |
|